Idioma:

Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer

Ashizawa, Tatsuto ; Iwahori, Tohru ; Yokoyama, Takayoshi ; Kihara, Yuu ; Konnno, Osamu ; Jyojima, Yoshimaro ; Akashi, Isao ; Nakamura, Yuuki ; Hama, Kouichirou ; Iwamoto, Hitoshi ; Segawa, Mai ; Takeuchi, Hironori ; Hirano, Toshihiko ; Nagao, Takeshi

Acta medica Okayama, 2010-02, Vol.64 (1), p.19-26 [Periódico revisado por pares]

Japan

Texto completo disponível

Citações Citado por

Enviar para

Título:
Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer
Autor: Ashizawa, Tatsuto ; Iwahori, Tohru ; Yokoyama, Takayoshi ; Kihara, Yuu ; Konnno, Osamu ; Jyojima, Yoshimaro ; Akashi, Isao ; Nakamura, Yuuki ; Hama, Kouichirou ; Iwamoto, Hitoshi ; Segawa, Mai ; Takeuchi, Hironori ; Hirano, Toshihiko ; Nagao, Takeshi
Assuntos: Aged ; Aged, 80 and over ; Antineoplastic Agents, Phytogenic - administration & dosage ; Antineoplastic Agents, Phytogenic - adverse effects ; Antineoplastic Agents, Phytogenic - blood ; Camptothecin - administration & dosage ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Camptothecin - blood ; Colorectal Neoplasms - complications ; Colorectal Neoplasms - drug therapy ; Female ; Gastrointestinal Neoplasms - complications ; Gastrointestinal Neoplasms - drug therapy ; Humans ; Kidney Failure, Chronic - complications ; Kidney Failure, Chronic - therapy ; Leukopenia - chemically induced ; Male ; Middle Aged ; Rectal Neoplasms - complications ; Rectal Neoplasms - drug therapy ; Renal Dialysis ; Stomach Neoplasms - complications ; Stomach Neoplasms - drug therapy
É parte de: Acta medica Okayama, 2010-02, Vol.64 (1), p.19-26
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
Descrição: We investigated changes in drug disposition and toxicities with CPT-11 in 15 dialysis patients with gastrointestinal cancers to clarify whether CPT-11 could be administered safely in such patients. For comparison, the same parameters were also investigated in 10 cancer patients not undergoing dialysis. Items investigated included (1) plasma concentrations of SN-38, SN-38G and CPT-11 at 0, 1, 12, 24, 36, 48 and 72 h after administration, together with a comparison of mean AUC values for 3 dose levels of CPT-11 (50, 60 and 70 mg/m2) in dialysis patients and controls; and (2) occurrence of adverse events. Several findings emerged from this study: (1) No significant difference was observed in the AUC for SN-38 or CPT-11 between the dialysis and control groups; (2) The AUC for SN-38G at each dose was significantly higher in dialysis patients; and (3) Grade 1-4 leucopenia was observed in 11 of the dialysis patients. One patient developed grade 4 leucopenia and died due to sepsis. Anorexia, diarrhea, nausea, alopecia and interstitial pneumonia occurred in 6 dialysis patients. We found changes in drug dispositions of CPT-11, SN-38 and SN-38G in dialysis patients, suggesting that hepatic excretion, especially that of SN-38G, was increased. No significant difference in occurrence of adverse events was observed between the 2 groups. This indicates that CPT-11 can be administered safely in patients on dialysis.
Editor: Japan
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer

Ashizawa, Tatsuto ; Iwahori, Tohru ; Yokoyama, Takayoshi ; Kihara, Yuu ; Konnno, Osamu ; Jyojima, Yoshimaro ; Akashi, Isao ; Nakamura, Yuuki ; Hama, Kouichirou ; Iwamoto, Hitoshi ; Segawa, Mai ; Takeuchi, Hironori ; Hirano, Toshihiko ; Nagao, Takeshi

Japan

Buscando em bases de dados remotas. Favor aguardar.